Podcasts about european brain council

In this episode, we are joined by Member of the European Parliament Tomas Zdechovský, Matthieu de Vilmorin, Past President of Schizo Oui, and Professor Merete Nordentoft, a leading expert in psychiatry at the University of Copenhagen. Together, they shed light on the pressing challenges and opportunities in the care and treatment of schizophrenia across Europe. Schizophrenia remains one of the most complex mental health conditions to manage, with profound and lasting impacts on young people and their families. While treatment options have evolved, persistent barriers—such as delayed diagnosis, discontinuity in care, and limited long-term support—continue to hinder recovery and quality of life for many. This episode explores the key findings from the second phase of the Rethinking Schizophrenia project, spearheaded by the European Brain Council in collaboration with the European Psychiatric Association. Drawing on insights from over 200 health practitioners across nine European countries—Belgium, Denmark, France, Germany, Hungary, Italy, Poland, Spain, and the UK—the project delivers a comprehensive analysis of care pathways and offers recommendations to improve early intervention, shared decision-making, and recovery-oriented approaches. With reflections from experts and powerful contributions from patient and caregiver advocates, we examine how to overcome stigma, close systemic gaps, and create a more inclusive and effective mental health system for all. Tune in now to hear how collaborative action and policy change can reshape schizophrenia care—and help support long-term recovery across Europe.

In the latest episode of the Brain Talks podcast, Sam Pauly is joined by a panel to discuss the importance of the pitch competition at the Brain Innovation Days and to present the Jury Prize-winning startup, BrainTale. Julie Rachline, the CEO of BrainTale and winner of the Jury Prize at the Pitch Competition, highlights the company's groundbreaking work in the field of neurological health. Along with Pascal Joncour, a member of the jury and partner at Convergence Partners, and Frédéric Destrebecq, Executive Director of the European Brain Council, the discussion focuses on the challenges and opportunities startups face in the medtech space. The episode sheds light on how collaborations, especially at events like Brain Innovation Days, can drive innovation and support new ventures in advancing brain health technologies.

In the latest episode of the Brain Talks podcast, Sam Pauly is joined by three expert guests: Karen Carr from AbbVie, Dr. Reto Agosti of the Zurich Headache Center, and Frédéric Destrebecq, Executive Director of the European Brain Council to discuss the challenges and opportunities in migraine care, exploring both clinical and policy perspectives.Together, they shed light on the barriers to effective diagnosis and treatment, the societal and economic impacts of migraines, and innovative solutions paving the way for better care. The discussion highlights the significant delays many patients face in receiving a proper diagnosis, often exacerbated by stigma and misperceptions about migraines. The conversation also underscores the immense burden migraines place on individuals, healthcare systems, and economies, calling for greater policy prioritization.Tune in to learn how the brain health community is breaking barriers and driving meaningful change for people living with migraines.

As the EU Health Technology Assessment (HTA) landscape transforms with the upcoming Joint Clinical Assessment (JCA), what does this mean for timely access to innovative therapies and reducing duplication of efforts across Member States? In this episode, Frédéric Destrebecq, Executive Director of the European Brain Council, sat down with Dr. Dimitrios Georgiopoulos, Senior Vice President and Global Franchise Head for Neurology & Immunology at Merck Healthcare, to discuss the opportunities and challenges of the new Health Technology Assessment Regulation, particularly for orphan and neurological treatments. Join us to explore how this new framework aims to harmonize methodologies, empower patient engagement, and shape a collaborative future for healthcare across the EU.

Welcome to Season 4 of Brain Talks!In this first episode, join our host Sam Pauly with special guests: Lisa Burke, Master of Ceremony for the 4th edition of the Brain Innovation Days, and Frédéric Destrebecq, Executive Director of the European Brain Council.Discover exclusive insights on the event's brand new theme, “Navigating the Brain Across a Lifetime,” learn more about the programme, but also its key sessions, new interactive experiences, and much more!

The Covid-19 pandemic shed a crude light on how instrumental research and innovation are in the European Union. This crisis revealed significant disparities and fractures between Member States. More importantly, patients living with neurological or mental disorders were heavily impacted by the pandemic, and faced tremendous challenges to maintain their access to care and to meet their medical needs.In this episode, Frederic Destrebecq, Executive Director of the European Brain Council, Christian Suojanen, Founder & CEO of Broadreach Global, and Professor Michel Goldman, renowned medical doctor and researcher, discuss the post-pandemic European landscape, and address the major challenges and opportunities for brain research and innovation in the EU.From fostering a collaborative climate within the wider brain community to an ambitious European Brain Research and Innovation Plan, join our journey on what it takes to make brain research and innovation a European priority for the 21st century.

In this episode, we dive deep into our society's enduring and complex relationship with alcohol. Host Anna Donaghey and guest Professor David Nutt, a renowned expert in neuropsychopharmacology, engage in a thought-provoking discussion about the glamorisation of alcohol in media, the impact of advertising on drinking habits, and the influence of the drinks industry on policies and public perception. They explore the historical and societal roots of alcohol's prevalence and shed light on the surprising realities of alcohol's effects on health and mental well-being. Together they reflect on the signs of a shift in alcohol culture and offer practical tips for mindful drinking.Here are the highlights:01:25 Alcohol's persistence due to historical and social factors.05:49 European drinking habits, influenced by history, differ.07:10 The point in UK history when alcohol consumption really grew.09:21 Why alcohol is our social drug of choice.15:03 The social benefits of alcohol. 20:25 The power of the drinks industry in government policy. 27:11 Obsession with wine and its health impacts.30:18 Alcohol: impacts on healthcare, taxes, and consumption.38:38 Fear of social isolation in drinking cessation.42:14 Years of investment led to a successful drink.43:50 Creating sociability through affordable alcohol alternatives.49:50 Awareness of drinking habits leads to consciousness.51:42 Drinking for stress relief can be concerning.About Professor David Nutt:David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology at Imperial College London. He is also the Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD) and President of the European Brain Council. David's Book: ‘Drink? The New Science of Alcohol And Your Health': https://www.amazon.co.uk/Drink-Science-Alcohol-Your-Health/dp/152939323XFind out more about the Gaba-based drink Sentia: https://sentiaspirits.com/Find out more about David's research and work into drugs: https://www.drugscience.org.uk/About the host, Anna:Anna is a certified Alcohol Mindset Coach, trained by Annie Grace of This Naked Mind. Drawing on her own journey out of alcohol addiction, she now helps others explore and control their drinking. With a career spanning 25 years as a Strategist in the Advertising industry, she combines her own lived experiences, with great insight into what makes us tick and what influences us to behave the way we do. Connect with Anna:Website: thebeliefscoach.comLinkedIn: linkedin.com/in/annadonagheyFacebook: facebook.com/thebeliefscoachInstagram: instagram.com/bigdrinkrethinkProduced by winteraudio.co.uk

I can't help but love it when some people f*ck with authority, especially when they are on the right side of history. Prof. David Nutt is one of those people. David is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences. He is also the Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD)) and President of the European Brain Council. But he's probably best known for up-ending everything we were taught about drugs in high school after he authored a study published in the Lancet that showed, through a multi-criteria analysis, that things like cannabis, psilocybin and LSD weren't nearly as harmful to people as was our then (and still, frankly) vice, alcohol. And we should all be grateful he did because in many ways that was a pivotal moment for the psychedelic renaissance and the start of a healthy reexamination of psychoactive compounds in our society. His recent book, Psychedelics: The Revolutionary Drugs That Could Change Your Life - a Guide From the Expert, was published in June 2023 and is now available for pre-order in Canada and the US. You can get your copy here.

Brain Talks are back for a third season!Join us in unveiling the highly anticipated 2023 edition of the Brain Innovation Days with Prof. Suzanne Dickson, President of the European Brain Council, and Frédéric Destrebecq, Executive Director of EBC.

There are~ 30 million people in Europe alone living with a rare condition, of which 75% have neurological symptoms. While significant progress has been made to address needs of these patients, key challenges remain including the scarcity of the expertise and fragmentation of research efforts that translate into delayed diagnosis, few disease modifying therapies, and difficulty in accessing adequate care. In this episode of Axiom Catalyst, we invited Frédéric Destrebecq, the Executive Director of the European Brain Foundation and European Brain Council to discuss how coordinated efforts between patient organisations, research and clinical networks, drug innovators and policy makers, can tackle these challenges and reduce the high burden posed by rare neurological disorders in Europe and beyond.

We're back from our summer break and our host, Sam Pauly, is delighted to be joined today by Dr Orla Galvin, Executive Director of the European Federation of Neurological Associations (EFNA) to discuss the important role patients play in guiding policy and leading advocacy in the brain space, particularly as the "experts" in their own brain conditions. A common phrase in the community always is, "nothing about us without us", a strong call to decision-makers to ensure that the people most affected by their decisions are involved from the beginning.Accompanied by Dr Elke De Witte, Head of Project Development at the European Brain Council, Sam explores the importance of patient involvement in policy and advocacy, the challenges and roadblocks faced to do so (and how to overcome them) and innovative approaches for improvement at present and in the future.For more information, visit http://efna.net/ and braininnovationdays.eu

We're taking a short summer break! We leave you with a short interview with the Executive Director of the European Brain Council, Frédéric Destrebecq, led by host Sam Pauly. Sam exchanges with Fred on the history and mission behind the birth of the Brain Innovation Days and what to expect at the 2nd in-person event this coming 11-12 October 2022 in Brussels, Belgium.Take a look at the programme now: https://www.braininnovationdays.eu/programme-2022/We hope to welcome you in Brussels later this year - wishing you all a great summer and see you soon.

Professor David Nutt, on the science behind hangovers and how new trends in the drinks market could help eradicate them for good. Alcohol is very much on the agenda as we approach the end of the year and look forward to a new one. Typically, in December we drink too much and in January, many of us think about cutting back. In this episode of the Table Talk podcast, Stefan Gates is joined by a very special guest who can offer some real insights into our relationship with alcohol, and specifically hangovers. Professor David Nutt is a former UK Government adviser and is currently employed at Imperial College London. He reveals the cost to the economy of people being hungover, why he thinks hangovers should be considered a form of illness, and how he believes synthetic alternatives to alcohol could eradicate some of its least desirable effects. David Nutt, DM, FRCP, FRCPsych, FBPhS FMedSci DLaws David Nutt is currently the Edmund J Safra Professor of Neuropsychopharmacology, Head of the Centre for Neuropsychopharmacology, and Director of the Centre for Psychedelic Research in the Division of Brain Science at Imperial College London.  He is also visiting professor at the Open University in the UK and Maastricht University in the Netherlands. Professor Nutt was the UK Government's drug adviser in the late 2000s.  He was removed from the position in 2009 for claiming that alcohol is more dangerous than ecstasy or LSD.  The following year, he published a study that showed that alcohol is more harmful to society than heroin or crack cocaine. Professor Nutt has held a number of significant scientific leadership positions including Presidencies of the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology and the European College of Neuropsychopharmacology as well as Chair of the UK Advisory Council on the Misuse of Drugs.  He has published over 500 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 35 books, including one for the general public; ‘Drugs Without the Hot Air', which won the Transmission book prize in 2014 for Communication of Ideas.  The second edition of this has just been released as has his autobiography ‘Nutt Uncut'. 

I had a great time speaking with Professor David Nutt. We discussed his research on how drugs impact and directly affect the human brain, but more notably what his research means to the world. Not only that, but we even dove a little into his chairman history of the Advisory Council on the Misuse of Drugs (ACMD), and the politics surrounding what happened when he revealed, "Ecstasy is no more Dangerous than Horseback Riding." His most recent research is about how DMT affects the brain. (Bio Below) Wikipedia - https://en.wikipedia.org/wiki/David_Nutt Website - https://www.imperial.ac.uk/people/d.nutt Artwork by Phillip Thor. More about him at https://linktr.ee/Philipthor_art. To watch the visuals with the trailer go to https://www.podcasttheway.com/trailers/ The Way Podcast - www.PodcastTheWay.com - Follow at Twitter / Instagram - @podcasttheway (Don't forget to Subscribe and Follow on streaming platforms too) As always thank you Don Grant for the Intro and Outro. Check out his podcast - https://threeinterestingthings.captivate.fm Intro guitar melody copied from Aiden Ayers at https://www.youtube.com/watch?v=7UiB9FMOP5s *The views expressed here are exclusively the views of The Way Podcast* Cropped Bio Summary: David Nutt is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs along with 27 books. In 2010 The Times Eureka science magazine included him in the 100 most important figures in British Science, and the only psychiatrist. David is currently Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD) and President of the European Brain Council. previously he was President of the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association (BNA), and the British Association of Psychopharmacology (BAP). In addition, he is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. He has edited the Journal of Psychopharmacology for over two decades and acts as the psychiatry drugs advisor to the British National Formulary. Previously he has been a member and then Chair of the Advisory Committee on the Misuse of Drugs (ACMD – 1998-2009), a member of the HEFCE/NHS Senior Lecturer Selection Panel and of the MRC Neuroscience Board. Other previous national contributions include serving as the medical expert on the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines, the Committee on NHS drugs as well as the Ministry of Defence Science Advisory Board. He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative “Brain science, addiction and drugs” that provided a 25-year vision for this area of science and public policy.

Prof Monica Di Luca, President of European Brain Council, presents the first episode of Brain Talks, the podcast launched by Brain Innovation Days.

How important is patient data to show the efficacy of medical cannabis?This week we're joined by Prof. David Nutt and David Badcock - from Drug Science - the UK's leading independent scientific body on drugs.This week, we explore Drug Science's newest observational study - Project Twenty21. We explore its aims to change the way medical cannabis is perceived and prescribed in the UK, it's operations, and the challenges of data collection on such a large project.Learn more about Project Twenty21 here: https://drugscience.org.uk/twenty21-is-now-live/→ View full show notes and summary here: https://www.cannabis-conversation.com/blogs/episode81About David BadcockDavid Badcock is the Chief Executive Officer of Drug Science, the leading independent scientific body on drugs in the UK, working to provide clear, evidence-based information without political or commercial interference. Previously David held strategic positions in the substance misuse treatment sector for over 15 years. During this time, he has met and worked with thousands of individuals who have turned their lives around to lead healthy, successful lives free from the burden of drug addiction. He was previously the Chief Executive Officer of Mainliners, a national drug treatment organisation focusing on harm reduction and blood borne viruses.  David has been a committee member for the Cambridge Ethnic Community Forum, Chair of The Alliance (supporting people who receive prescribed medication for drug dependency), and Scientific Committee member for the influential London Joint Working Group for Substance Misuse and Hepatitis C. David specialises in creating unique partnerships with organisations and companies who share a joint vision to help the most marginalised and vulnerable members of our communities.About Professor David NuttProfessor David Nutt is the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Sciences, Imperial College London. He has published over 400 original research papers, 8 government reports on drugs and 31 books, including one for the general public, Drugs: without the hot air, winning the Transmission Prize in 2014. He was formerly the President of the European Brain Council and is the founding Chair of DrugScience. Professor Nutt broadcasts widely to the general public both on radio and television. In 2010, The Times Eureka science magazine voted him one of the 100 most important figures in British ScienceQuotablesIn reality, medicine is about trying things out in patients 24:58Doctors are scared of doing anything they haven't been taught to do… there is nothing in medical school curriculum about medical cannabis 10:52The problem with medical cannabis in the UK… is getting doctors to accept it does work 13:00ResourcesDrug Science Website: https://drugscience.org.uk/Drug Science Wikipedia Page: https://en.wikipedia.org/wiki/DrugScienceFollow Drug Science on LinkedIn: https://www.linkedin.com/company/drugscience-ltdFollow Drug Science on Twitter: https://twitter.com/Drug_Science?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5EauthorFollow Prof. David Nutt on Twitter: https://twitter.com/ProfDavidNutt

Nick and Ash discuss the week in drug news, policy and events.Professor David Nutt has been in Australia for the VAADA (Victorian Alcohol And other Drugs Association) Conference 2019 and also helped launch Mind Medicine Australia. Professor Nutt is the founder Chair of DrugScience.org.uk (formerly the Independent Scientific Committee on Drugs – ISCD) and has held many leadership positions in both the UK and European academic scientific and clinical organisations including the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology and the UK Advisory Council on the Misuse of Drugs. He is a Fellow of the Royal Colleges of Physicians, of Psychiatrists and the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders courses and a member of the International Centre for Science in Drug Policy.

Brain disorders are becoming more and more prevalent in the population. Kim’s and Alessia’s guest - Frédéric Destrebecq, executive director of European Brain Council (EBC) - is here to tell us about how society can cope with this tendency, discussing prevention and treatment of brain diseases as well as topics like effects of depression, mental illness stigma, stress disorders and burnout syndrome. European Brain Council is a non-profit organization that brings together patient associations, research institutions, and representatives of the relevant industries, with a mission to improve the quality of life among people suffering from neurological disorders. Founded in Brussels in 2002, EBC have spent the last 16 years facilitating communication between their member organizations, as well as between research, industry and policy-makers. Furthermore, they have been influencing European Commission and European Parliament to invest more in brain health. Besides the pan-European level, EBC works with National Brain Councils and National Action Groups (check this map to see if you country has one) too, and on global partnerships.Kim Baden-Kristensen is the co-founder and CEO of Brain+, a digital therapeutics company that helps people with brain disorders and injuries to recover their fundamental cognitive brain functions and daily life capabilities by using an app-based cognitive rehabilitation platform, which is developed in close collaboration with patients, clinicians and researchers. https://www.linkedin.com/in/kbadenk/ Alessia Covello is a life science IT consultant working in the field of healthcare technology implementation, and advocating for better services for people with brain conditions and learning disabilities. https://www.linkedin.com/in/alessiacovello/ Discussion points include: ● Brain health statistics: prevalence in the population, costs of treatment, current issues (4:00 - 16:20)● The role of education and awareness, especially in work environments (13:22)● Technology in hospital care and daily life (16:24-22:00)● The role, the achievements, and the priorities of EBC (22:15-27:30) ● Treatment and prevention - what is more important? (27:44-33:45) ● Allocation of the EU sources to brain research (34: 04-46:00)● Role of the industry (46:36-48:30)● Patient-centered care (48.38-50:45)Disclaimer:All references to products, companies, and organizations in this podcast and the article that accompanies it are included with the purpose to inform, rather than promote or advertise. The podcast authors do not receive financial compensation for any of these references.

"Chipping Barnet Labour Presents" is excited to welcome Professor David Nutt for the next in our series of free talks. Professor Nutt is the director of the Neuropsychopharmacology Unit in the Division of Brain Sciences, and a previous advisor to the government on drugs policy. He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative “Brain science, addiction and drugs” that provided a 25-year vision for this area of science and public policy. He broadcasts widely to the general public both on radio and television including BBC science and public affairs programmes on therapeutic as well as illicit drugs, their harms and their classification. This talk focussed on the history of drug controls over the past century and how they may have done more harm than good. Professor Nutt showed multi-criteria decision analyses on the different harms of different drugs and will discuss new approaches to policy. Finally he explains how New Labour fell in to the trap of being harder on drugs than the Tories, and he discussed the need for the party to now develop a more honest and evidence based approach to drug policy. Professor Nutt is currently President of the European Brain Council. Previously he has been President of the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association (BNA) and the British Association of Psychopharmacology (BAP). In addition he is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences.

Before wowing two full rooms of people with an impassioned defence of reason, logic and the scientific method, Prof. David Nutt sat down with our very own Claudia Schaffner for a little chat. David Nutt is a psychiatrist at Imperial College London. Here he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books. He is currently the President of the European Brain Council and Founding Chair of DrugScience (formerly the Independent Scientific Committee on Drugs (ISCD). He broadcasts widely to the general public both on radio and television. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science. Twitter: @ProfDavidNutt

We're back! Finally! And we have a brilliant talk for our first episode after the Fringe - Professor David Nutt! We had two full rooms (main and overspill) for this event - our most attended event in ages - and it was a treat to hear somebody of his calibre entertain and enthral us with his thoughts. His talk explores the inconsistencies and injustices that emerge from the un-scientific methods we use to control alcohol and other drugs. He explains how there are more rational and functional approaches and encourage Scotland to rise to the challenge of breaking out of the current flawed position. David Nutt is a psychiatrist at Imperial College London. Here he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books. He is currently the President of the European Brain Council and Founding Chair of DrugScience (formerly the Independent Scientific Committee on Drugs (ISCD). He broadcasts widely to the general public both on radio and television. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science. Twitter: @ProfDavidNutt